Pan-Specific Prediction of Peptide-MHC Class I Complex Stability, a Correlate of T Cell Immunogenicity.

PubWeight™: 0.79‹?›

🔗 View Article (PMID 27402703)

Published in J Immunol on July 08, 2016

Authors

Michael Rasmussen1, Emilio Fenoy2, Mikkel Harndahl1, Anne Bregnballe Kristensen1, Ida Kallehauge Nielsen1, Morten Nielsen3, Søren Buus4

Author Affiliations

1: Laboratory of Experimental Immunology, Department of International Health, Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 N Copenhagen, Denmark;
2: Instituto de Investigaciones Biotecnológicas, Universidad Nacional de San Martín, San Martín, B 1650 HMP, Buenos Aires, Argentina; and.
3: Instituto de Investigaciones Biotecnológicas, Universidad Nacional de San Martín, San Martín, B 1650 HMP, Buenos Aires, Argentina; and Center for Biological Sequence Analysis, Technical University of Denmark, 2800 Kongens Lyngby, Denmark.
4: Laboratory of Experimental Immunology, Department of International Health, Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2200, Denmark; sbuus@sund.ku.dk.

Articles cited by this

MHC ligands and peptide motifs: first listing. Immunogenetics (1995) 7.78

Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci (2003) 5.94

NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res (2008) 4.53

NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS One (2007) 3.99

NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics (2008) 3.59

Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics (2005) 2.91

Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinformatics (2007) 2.83

Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers. Bioinformatics (2008) 2.69

Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J Immunol (1996) 2.11

Immune epitope database analysis resource. Nucleic Acids Res (2012) 2.09

A quantitative analysis of the variables affecting the repertoire of T cell specificities recognized after vaccinia virus infection. J Immunol (2007) 2.00

The kinetic stability of MHC class II:peptide complexes is a key parameter that dictates immunodominance. Immunity (2005) 1.88

NetMHCcons: a consensus method for the major histocompatibility complex class I predictions. Immunogenetics (2011) 1.57

NetCTLpan: pan-specific MHC class I pathway epitope predictions. Immunogenetics (2010) 1.37

Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100. Cancer Res (2009) 1.26

Peptide-MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity. Eur J Immunol (2012) 1.24

Properties of MHC class I presented peptides that enhance immunogenicity. PLoS Comput Biol (2013) 1.19

Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinformatics (2015) 1.18

Real-time, high-throughput measurements of peptide-MHC-I dissociation using a scintillation proximity assay. J Immunol Methods (2010) 1.18

Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity. Proc Natl Acad Sci U S A (1995) 1.11

Amino acid similarity accounts for T cell cross-reactivity and for "holes" in the T cell repertoire. PLoS One (2008) 1.11

In vivo CTL induction with point-substituted ovalbumin peptides: immunogenicity correlates with peptide-induced MHC class I stability. Vaccine (1995) 1.10

The impact of HLA-B micropolymorphism outside primary peptide anchor pockets on the CTL response to CMV. Eur J Immunol (2007) 1.06

Relationship between kinetic stability and immunogenicity of HLA-DR4/peptide complexes. Eur J Immunol (2002) 1.05

Uncovering the peptide-binding specificities of HLA-C: a general strategy to determine the specificity of any MHC class I molecule. J Immunol (2014) 0.97

NetMHCstab - predicting stability of peptide-MHC-I complexes; impacts for cytotoxic T lymphocyte epitope discovery. Immunology (2014) 0.93

NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets. Genome Med (2016) 0.92

Secondary anchor polymorphism in the HA-1 minor histocompatibility antigen critically affects MHC stability and TCR recognition. Proc Natl Acad Sci U S A (2009) 0.89

HLA-B27 subtype polymorphism and CTL epitope choice: studies with EBV peptides link immunogenicity with stability of the B27:peptide complex. J Immunol (1998) 0.89

Improved immunogenicity of an immunodominant epitope of the HER-2/neu protooncogene by alterations of MHC contact residues. J Immunol (2004) 0.85

Steric hindrance and fast dissociation explain the lack of immunogenicity of the minor histocompatibility HA-1Arg Null allele. J Immunol (2009) 0.83

Selective amino acid substitutions of a subdominant Epstein-Barr virus LMP2-derived epitope increase HLA/peptide complex stability and immunogenicity: implications for immunotherapy of Epstein-Barr virus-associated malignancies. Eur J Immunol (1999) 0.82

Dendritic cell vaccination induces cross-reactive cytotoxic T lymphocytes specific for wild-type and natural variant human immunodeficiency virus type 1 epitopes in HLA-A*0201/Kb transgenic mice. Clin Immunol (2001) 0.81

T-cell recognition is shaped by epitope sequence conservation in the host proteome and microbiome. Immunology (2016) 0.78

Immunogenicity of tumor peptides: importance of peptide length and stability of peptide/MHC class II complex. Cancer Immunol Immunother (1999) 0.77